Dr. Prem Narayan Gupta

Senior Principal Scientist

Pharmacology Division

CSIR – Indian Institute of Integrative Medicine,Canal Road, Jammu – 180001
Email: pngupta[at]iiim[dot]res[dot]in

Profile

Bio Sketch

Dr. Gupta is Senior Principal Scientist at CSIR-Indian Institute of Integrative Medicine, Jammu, India. He earned PhD in Pharmaceutical Sciences from Dr. HSG Central University, Sagar. Dr. Gupta conducted postdoctoral research work in Drug Delivery & Biomaterial Research Group with Prof. Karl Malcolm at School of Pharmacy, Queen’s University of Belfast, United Kingdom with the prestigious fellowship from Bill & Melinda Gates foundation, USA & Wellcome trust, UK. The research interest of Dr. Gupta’s research group at CSIR-IIIM include pre-clinical formulation development for discovery molecules for investigation/modulation of pharmacokinetic profile/pharmacological behaviour, controlled and targeted drug delivery, solubility enhancement, modulation of bioavailability using pharmaceutical and pharmacological approaches, cancer nanomedicine, drug delivery approaches for modulation of tumor microenvironment and novel drug delivery systems. Dr. Gupta is a member of many professional bodies and research grant reviewer for various national & international research funding agencies.

Education

Degree	Subjects	University	Qualifying Year
PhD	Pharmaceutical Sciences	Department of Pharmaceutical Sciences, Dr. HSG Central University, Sagar (MP)	2009
M.Pharm	Pharmacy	Department of Pharmaceutical Sciences, Dr. HSG Central University, Sagar (MP)	2002
B.Pharm	Pharmacy	Department of Pharmaceutical Sciences, Dr. HSG Central University, Sagar (MP)	2000

Position Held

Position Held	Period	Organization
Senior Principal Scientist	2021-Present	CSIR-Indian Institute of Integrative Medicine, Jammu, India
Principal Scientist	2016-2021	CSIR-Indian Institute of Integrative Medicine, Jammu, India
Senior Scientist	2010-2016	CSIR-Indian Institute of Integrative Medicine, Jammu, India
Postdoctoral Research Fellow	2009-2010	Drug Delivery & Biomaterial Research Group, School of Pharmacy, Queen’s University of Belfast, United Kingdom
Project Fellow	2003-2003	National Institute of Immunology, New Delhi, India

Area of Expertise

High lipophilicity and low water solubility are increasingly common characteristics of drug discovery molecules and clinical drugs. The preclinical formulations are necessary to acquire sufficient systemic exposure in order to select, optimize and advance compounds on a broad range of pharmaceutically related properties/profiles including pharmacology, pharmacokinetics and toxicology. Also, a number of clinical drugs possesses sub-optimal physicochemical properties and are associated with compromised bioavailability and adverse effects. Exploration of various pharmaceutical and pharmacological drug delivery strategies are needed to realize true potential of drug discovery molecules/clinical drugs. In these directions our research work focuses on pre-clinical formulation development for discovery molecules, utilization of pharmaceutical and pharmacological approaches for improved efficacy of bioactive molecules, strategies for solubility enhancement/modulation of bioavailability, controlled and targeted drug delivery, formulation strategies for modulation of macrophage recognition, cancer nanomedicine, drug delivery approaches for modulation of tumor microenvironment and novel drug delivery systems.

Project Involved / Ongoing Projects

Projects

Pre-clinical Pharmacological Evaluation, PK/PD/Toxicity and Safety Studies of identified hits/leads
Exploring the Himalayan plants with immunomodulant and galactagogue properties in connection to animal health to optimize cattle productivity
Targeted nano-carrier based tumor-associated macrophage polarization and rationally designed natural product mediated strategy for improved triple negative breast cancer therapy
CSIR-Aroma mission project

Publications and Patents

Publications

Haq SA, Paudwal G, Banjare N, Andrabi NI, Wazir P, Nandi U, Ahmed Z, Gupta PN, Sustained release polymer and surfactant based solid dispersion of andrographolide exhibited improved solubility, dissolution, pharmacokinetics, and pharmacological activity, Int. J. Pharm, 2024, 651, 123786.
Sandha KK, Behera C, Chibber P, Kumar R, Kumar A, Mondhe DM, Singh GD, Gupta PN. Antifibrotic agent mediated tumor microenvironment modulation and improved nanomedicine delivery in solid tumor, Molecular Pharmaceutics, 2023, 20, 2927-2941.
Shukla MK, Behera C, Chakraborty S, Kour KK, Goswami A, Gupta PN. Tumor micro-environment targeted collagenase-modified albumin nanoparticles for improved drug delivery. J. Drug Del. Sci. Technol. 2022, 71, 103366.
Dhanwal V, Katoch A, Nayak D, Chakraborty S, Gupta R, Kumar A, Gupta PN, Singh N, Kaur N, Goswami A. Benzimidazole-based organic-inorganic gold nanohybrids suppress invasiveness of cancer cells by modulating EMT signaling cascade, ACS Applied Biomaterials, 2021, 4, 470–482.
Saneja A, Kumar R, Mintoo MJ, Dubey RD, Sangwan PL, Mondhe DM, Panda AK, Gupta PN. Gemcitabine and betulinic acid co-encapsulated PLGA−PEG polymer nanoparticles for improved efficacy of cancer chemotherapy, Materials Science and Engineering: C, 2019, 98, 764-771.
Dheer D, Gupta R, Singh D, Magotra A, Singh GD, Gupta PN, Shanker R, Hyaluronic acid-tacrolimus bioconjugate: synthesis, characterization, and pharmacokinetic investigation of an acid responsive macromolecular prodrug, ACS Applied Biomaterials, 2019, 2, 4728-4736.
Saneja A, Nayak D, Srinivas M, Kumar A, Khare V, Katoch A, Goswami A, Vishwakarma RA, Sawant SD, Gupta PN, Development and mechanistic insight into enhanced cytotoxic potential of hyaluronic acid conjugated nanoparticles in CD44 overexpressing cancer cells, Eur J. Pharm Sci. 2017, 97,79-91.
Khare V, Singh A, Mahajan G, Alam N, Kour S, Gupta M, Kumar A, Singh GD, Singh SK, Saxena AK, Mondhe DM, Gupta PN, Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy, Eur. J. Pharm Sci., 2016, 92, 183-193.
Alam N, Qayum A, Kumar A, Khare V, Singh S, Sharma PR, Singh SK, Koul S, Gupta PN. Improved efficacy of cisplatin in combination with a nano-formulation of pentacyclic triterpenediol. Materials Science and Engineering C, 2016, 68, 109-116.
Dubey R, Alam N, Saneja A, Khare V, Kumar A, Vaidh S, Mahajan G, Sharma PR, Singh SK, Mondhe DM, Gupta PN, Development and evaluation of folate functionalized nanoparticles for targeted delivery of gemcitabine, International Journal of Pharmaceutics 2015, 492, 80-91.
Alam N, Khare V, Dubey R, Saneja A, Singh GD, Sharma N, Chandan BK, Gupta PN, Biodegradable polymeric system for cisplatin delivery: Development, in vitro characterization and investigation of toxicity profile, Material Science & Engineering C, 2014, 38, 85-93.
Gupta PN, Pattani A, Curran RM, Andrews GP, Morrow RJ, Woolfson AD, Malcolm RK. Development of liposome gel-based formulations for intravaginal delivery of the recombinant HIV-1 envelope protein CN54gp140. Eur J Pharm Sci. 2012, 46, 315-322.
Pattani A, McKay PF, Curran RM, McCaffrey J, Gupta PN, Lowry D, Kett VL, Shattock RJ, McCarthy HO, Malcolm RK. Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form, Vaccine, 2012, 30, 2778-2785.

Awards / Honours

Awards and Honours

Ranbaxy Science Scholar Award (2007)
Formulation & Drug Delivery Leadership Award (2019).
Bill & Melinda Gates foundation (USA) & Welcome trust (UK) funded postdoc fellowships (2009-2010).
National Doctoral Fellowship from All India Council of Technical Education, New Delhi (2006).
Senior Research Fellowship from Indian Council of Medical Research, New Delhi(2004).